Merrimack Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Merrimack Pharmaceuticals has been growing earnings at an average annual rate of 76.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
76.3%
Earnings growth rate
76.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -6.3% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05Revenue & Expenses BreakdownBeta
How Merrimack Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -1 | 2 | 0 |
30 Sep 23 | 0 | -1 | 2 | 0 |
30 Jun 23 | 0 | -2 | 2 | 0 |
31 Mar 23 | 0 | -2 | 2 | 0 |
31 Dec 22 | 0 | -2 | 2 | 0 |
30 Sep 22 | 0 | -2 | 2 | 0 |
30 Jun 22 | 0 | -2 | 2 | 0 |
31 Mar 22 | 0 | -2 | 2 | 0 |
31 Dec 21 | 0 | -2 | 3 | 0 |
30 Sep 21 | 0 | -3 | 3 | 0 |
30 Jun 21 | 0 | -4 | 3 | 0 |
31 Mar 21 | 0 | -4 | 4 | 0 |
31 Dec 20 | 0 | -3 | 5 | 0 |
30 Sep 20 | 0 | -3 | 6 | 0 |
30 Jun 20 | 0 | -2 | 10 | 0 |
31 Mar 20 | 0 | -11 | 12 | 0 |
31 Dec 19 | 0 | -21 | 13 | 0 |
30 Sep 19 | 0 | -33 | 15 | 0 |
30 Jun 19 | 0 | -45 | 14 | 0 |
31 Mar 19 | 0 | -53 | 15 | 0 |
31 Dec 18 | 0 | -61 | 15 | 0 |
30 Sep 18 | 0 | -60 | 16 | 0 |
30 Jun 18 | 0 | -53 | 16 | 0 |
31 Mar 18 | 0 | -64 | 27 | 0 |
31 Dec 17 | 0 | -75 | 28 | 0 |
30 Sep 17 | 0 | -102 | 35 | 0 |
30 Jun 17 | 0 | -123 | 38 | -53 |
31 Mar 17 | 0 | -146 | 31 | -26 |
31 Dec 16 | 0 | -155 | 32 | 0 |
30 Sep 16 | 21 | -163 | 40 | -110 |
30 Jun 16 | 38 | -179 | 51 | -21 |
31 Mar 16 | 74 | -151 | 55 | -7 |
31 Dec 15 | 0 | -152 | 24 | 0 |
30 Sep 15 | 102 | -110 | 47 | 241 |
30 Jun 15 | 113 | -95 | 38 | 206 |
31 Mar 15 | 105 | -90 | 33 | 165 |
31 Dec 14 | 103 | -83 | 31 | 0 |
30 Sep 14 | 77 | -107 | 28 | 0 |
30 Jun 14 | 56 | -118 | 25 | 0 |
31 Mar 14 | 46 | -130 | 22 | 0 |
31 Dec 13 | 48 | -131 | 21 | 141 |
30 Sep 13 | 54 | -123 | 19 | 0 |
30 Jun 13 | 59 | -106 | 18 | 0 |
Quality Earnings: MACK is currently unprofitable.
Growing Profit Margin: MACK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MACK is unprofitable, but has reduced losses over the past 5 years at a rate of 76.3% per year.
Accelerating Growth: Unable to compare MACK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MACK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MACK has a negative Return on Equity (-6.3%), as it is currently unprofitable.